The evaluation of the efficacy of a switch from GnRH agonist to GnRH antagonist in prostate cancer patients who relapsed during combined androgen blockade.
- Conditions
- prostate cancer
- Registration Number
- JPRN-UMIN000013514
- Lead Sponsor
- Tokai Urological Clinical Trial Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 50
Not provided
1. receiving chemotherapeutic agents (including estramustine), corticosteroids, hormone agents except for GnRH agonist and non-steroidal antiandrogens, or investigational drugs 2. patients who never responded to CAB 3. patients with active multiple cancers 4. patients with clinical symptoms such as bone pain and nerve injury as a result of a spinal cord compression 5. prior treatment with local therapy (radical prostatectomy or radiotherapy) 6. patients with severe hepatic dysfunction (Child-Pugh class C) 7. patients with HIV or chronic active hepatitis B/C 8. history of acute myocardial infarction, severe or unstable angina, coronary or peripheral arterial revascularization, symptomatic congestive heart failure, cerebral vascular disease, transient ischemic attacks, or pulmonary embolism within 6 months before registration 9. patients with interstitial pneumonia or past history of interstitial pneumonia 10. patients with a brain tumor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method